8-K: Ionis Pharmaceuticals Announces Positive Phase 3 Results for Donidalorsen in Hereditary Angioedema

Ionis Pharmaceuticals reported positive results from Phase 3 trials of donidalorsen, showing significant reductions in hereditary angioedema attacks and improved quality of life for patients.

Summary

• Ionis Pharmaceuticals announced positive results from the OASIS-HAE and OASISplus studies for donidalorsen, an investigational medicine for hereditary angioedema (HAE).
• The studies demonstrated significant and sustained reductions in HAE attack rates with both monthly and every two-month dosing of donidalorsen.
• Patients switching from prior prophylactic treatments to donidalorsen experienced a 62% further reduction in mean monthly HAE attack rates from baseline.
• 84% of patients who switched to donidalorsen reported a preference for it over their previous treatment.
• The OASIS-HAE study showed an 81% reduction in monthly HAE attack rates with monthly dosing and a 55% reduction with every two-month dosing compared to placebo.
• The open-label extension of the study showed continued improvement in attack rates, with a 93% and 92% improvement from baseline for monthly and every two-month dosing, respectively.
• Donidalorsen was well-tolerated with a favorable safety profile across all cohorts, with most adverse events being mild or moderate.

Sentiment

Score: 9

Explanation: The document presents overwhelmingly positive results from clinical trials, indicating a significant advancement in the treatment of HAE. The high efficacy and favorable safety profile of donidalorsen, along with strong patient preference, suggest a very positive outlook for the drug's potential market success.

Positives

• Donidalorsen demonstrated significant reductions in HAE attack rates.
• The drug showed continued improvement in attack rates over time.
• Patients experienced improved quality of life measures.
• Donidalorsen has a favorable safety and tolerability profile.
• A high percentage of patients preferred donidalorsen over previous treatments.
• The drug can be self-administered via an auto-injector.

Negatives

• One patient in the donidalorsen every two-month group discontinued due to patient noncompliance and a treatment emergent adverse event.
• Injection site reactions were the most common adverse event.

Risks

• The drug is still investigational and requires regulatory approval.
• There are inherent risks in the process of discovering, developing, and commercializing new medicines.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Ionis plans to file a New Drug Application with the U.S. FDA this year and Otsuka Pharmaceutical Co., Ltd. is preparing to submit a Marketing Authorization Application to the European Medicines Agency this year.

Management Comments

• Brett Monia, Ph.D., chief executive officer of Ionis, stated that the results position donidalorsen to advance the prophylactic treatment paradigm for people living with HAE.
• Kenneth Newman, M.D., senior vice president of clinical development at Ionis, said that donidalorsen significantly reduced HAE attack rates and has a unique profile that may address the needs of people with HAE.
• Marc Riedl, M.D., M.S., clinical director, U.S. HAEA Angioedema Center, noted that the OASISplus study demonstrated patients can change therapy to donidalorsen without increased breakthrough attacks while improving quality of life and disease control.

Industry Context

The announcement is significant as it addresses the unmet need for effective prophylactic treatments for HAE, a rare and potentially life-threatening condition. The positive results could position donidalorsen as a strong competitor in the HAE treatment market.

Comparison to Industry Standards

• Current prophylactic treatments for HAE include lanadelumab, berotralstat, and C1-esterase inhibitors, which were used as comparators in the switch cohort of the OASISplus study.
• The study results indicate that donidalorsen may offer superior disease control and patient preference compared to these existing treatments, with 84% of patients preferring donidalorsen after switching.
• The 62% further reduction in mean monthly HAE attack rates in the switch cohort suggests a potential advantage over existing therapies.
• The high levels of disease control and quality of life improvements observed in the study are also notable when compared to the outcomes of other HAE treatments.

Stakeholder Impact

• Shareholders may see a positive impact due to the potential for a new revenue stream from donidalorsen.
• Patients with HAE may benefit from a new, more effective treatment option.
• Employees may see increased job security and growth opportunities.
• The company's reputation may be enhanced due to the successful clinical trial results.

Next Steps

• Ionis plans to file a New Drug Application with the U.S. FDA.
• Otsuka Pharmaceutical Co., Ltd. is preparing to submit a Marketing Authorization Application to the European Medicines Agency.
• Ionis will continue to advance donidalorsen as part of its growing independent commercial pipeline.

Key Dates

Keywords

donidalorsen, hereditary angioedema, HAE, Ionis Pharmaceuticals, prophylactic treatment, RNA-targeted medicine, OASIS-HAE, OASISplus, clinical trial, prekallikrein